viewBioTime, Inc.

BioTime shares pop following positive preclinical results from its HyStem drug delivery platform

Results suggest that HyStem may be able to restore brain function following an ischemic stroke by reducing neuroinflammation

Scientist sitting in a lab holding equipment
BioTime is a clinical-stage biotech that develops therapies for degenerative diseases

BioTime Inc (NYSE:BTX) shares are on the rise following the publication of positive preclinical results from its HyStem cell and drug delivery platform.

The results show that the delivery technology may alleviate ischemic brain injury and restore function by reducing neuroinflammation.

Shares of BioTime were up nearly 6% to $1.51 in Tuesday afternoon trading.

READ: Marinus Pharmaceuticals Inc issues bullish report on anti-epileptic drug ganaxolone

Ischemia occurs when there is insufficient blood flow to an organ. It can be difficult to administer drugs to a brain that has been affected by an ischemic stroke due to the blood-brain barrier.

“Results from this study, designed to simulate the clinical needs of human stroke, underscore the ability of our proprietary HyStem delivery technology to target therapy dosing to a specific anatomical site such as to the ischemic core, and minimize dissipation to surrounding tissues,” said Senior Vice President and Global Head of Product Development Francois Binette in the company’s press release.

The clinical-stage biotech focuses on the development and commercialization of novel therapies for the treatment of degenerative diseases.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Quick facts: BioTime, Inc.

Price: - -

Market: NYSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Medexus Pharmaceuticals sees record revenue and more strong growth beyond 1Q...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) CEO Ken d’Entremont tells Proactive the specialty pharmaceutical company posted record revenue of C$27.5 million during its fiscal first-quarter thanks to strong sales of its four leading drug products. d’Entremont says he sees because the...

44 minutes ago

2 min read